Elanco Animal Health Inc reported second-quarter 2026 results with revenue up 10% year over year and a return to profitability, driven by pet health and farm animal volume gains, pricing, and recent product launches.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$1.37B$1.24B10.2% | Net income²$54M$11M390.9% | Diluted EPS³$0.11$0.02450% |
¹ Reported as “Revenue”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by pet health and farm animal volume gains and pricing, with omnichannel distribution across veterinary clinics, retail and e-commerce.
- New product launches including Zenrelia, Credelio Quattro and Befrena are gaining adoption and contributing incremental sales.
- Completed the AHV acquisition on April 30, 2026, to expand the farm animal portfolio; the acquisition contributed modest revenue in 2026.
- Ongoing 2025 Restructuring Plan includes R&D consolidation (Monheim exit, Indy expansion) and exit of the Kansas City plant to drive future savings.
- Approximately 52% of revenue is generated in non‑USD markets, affecting geographic mix and results.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.